I have enough material now to write a comprehensive, well-sourced earnings preview. Let me compose it.# Biogen (BIIB) Q2 2026 Earnings Preview Report Date: Wednesday, July 29, 2026, before market open | Call: 8:30 a.m. ET
Biogen shares have been volatile heading into the quarter, trading in the $190–$217 range over the past two months and closing around $205.65 on July 28. The stock has been whipsawed by a mix of positive commercial/M&A news and a high-profile pipeline disappointment in mid-July. Consensus expects a sharp year-over-year decline in EPS, but this is almost entirely a function of one-time acquisition-related charges rather than deteriorating core operations.
Analyst estimates for Q2 cluster around $3.13–$3.24 non-GAAP EPS (down roughly 41-43% year-over-year from $5.47) on revenue of approximately $2.43–$2.47 billion. Zacks' consensus specifically pegs the quarter at $2.47 billion in sales and $0.79 (GAAP) per share, while other estimates for adjusted EPS run closer to $3.13-$3.24. Biogen has beaten bottom-line estimates in each of the last four quarters, including a 21% beat last quarter, so the bar for a "beat" on an apples-to-apples core basis is arguably not that high — the real driver of the reported EPS decline is disclosed, non-operating acquisition charges (see below).
Biogen pre-announced via 8-K that Q2 and Q3 non-GAAP/GAAP results will absorb substantial acquired IPR&D expense: - Q2 2026: ~$164 million pre-tax, a roughly $0.95/share hit to GAAP and non-GAAP EPS. - Q3 2026: an anticipated $290–320 million charge tied to "potential milestones and transactions that have not yet closed," a $1.75–$1.95/share impact.
These charges explain much of the headline EPS decline versus a year ago and versus the original guidance. Investors should look past the GAAP/non-GAAP headline miss narrative and focus on underlying growth-product trends and updated full-year guidance.
Full-year 2026 non-GAAP EPS guidance has already been revised twice this year, purely due to business-development charges, not operational weakness: - February 2026 (original): $15.25–$16.25 - April 2026 (Q1 report), excluding Apellis: lowered to $14.25–$15.25, reflecting roughly $1.00/share of acquired IPR&D from deals like TJ Bio (felzartamab China rights) and a STELLAR-1 milestone.
Management explicitly said it would not provide consolidated guidance including Apellis until the Q2 report, so this print is the first opportunity to get a combined outlook. Expect: 1. A new FY26 EPS range folding in Apellis dilution/accretion dynamics, financing costs (~$120–130 million of non-GAAP other expense guided for 2026), and the newly disclosed Q2/Q3 IPR&D charges. 2. Updated revenue guidance — prior guidance called for total revenue to decline by a mid-single digit percentage for 2026 as compared to 2025 as further declines in multiple sclerosis product revenue, excluding VUMERITY, are expected to be partially offset by increases in revenue from growth products, now with SYFOVRE/EMPAVELI added. 3. Commentary on delevering — management said it expects strong combined cash flow generation to provide the opportunity to delever by the end of 2027 after funding the deal with $3.6 billion of cash and $2 billion of bank borrowings.
Biogen closed its $5.3 billion acquisition of Apellis Pharmaceuticals on May 14, 2026, so Q2 will be the first full quarter to include Apellis's commercial products. Key deal facts: - The tender offer paid $41 per share in cash and one contractual, non-transferable contingent value right per share representing the right to receive contingent cash payments of up to an aggregate of $4 in cash upon the achievement of certain annual global net sales thresholds for SYFOVRE. - The deal adds two best-in-class commercialized products, EMPAVELI® and SYFOVRE®, significantly bolstering Biogen's near-term growth outlook and accelerating the Company's expansion into nephrology, with the combined products having recorded $689 million in net product revenue in 2025. - Management believes the deal will be accretive to Biogen's Non-GAAP diluted EPS in 2027 and is expected to materially increase Biogen's non-GAAP EPS compound annual growth rate (CAGR) through the end of the decade. - Apellis also brings an established nephrology commercial and medical infrastructure to accelerate Biogen's launch readiness for felzartamab, with a first Phase 3 readout in antibody-mediated rejection in kidney transplant patients anticipated in the first half of 2027.
On the Q1 call, CEO Chris Viehbacher framed the deal as transformational to the growth narrative: "If we just take what Wall Street thinks Biogen is going to do... it's roughly flat through 2030. Now when you look at what Apellis can do is this allows Biogen to start growing now... And then the pipeline starts to read out." He also noted an investor's framing that Biogen previously had "a pipeline coming on a flat business. Now I see a pipeline coming on a growing business." Investors should listen for early commentary on SYFOVRE/EMPAVELI integration, sales-force synergies, and DTC spending plans for SYFOVRE, which management indicated it intends to increase given the large ~500,000 untreated patient pool in geographic atrophy that Apellis's targeted physician offices already call on.
Growth products (ex-Apellis) were $851 million in Q1, up 12% y/y and now exceed remaining MS product revenue combined: - LEQEMBI: Q1 end-market revenue was $168 million, up 74% y/y, with continued sequential growth in the U.S., Japan, and China, and it remains the market leader by total patient share in the U.S., Japan and China. The bigger near-term catalyst: the FDA approved LEQEMBI IQLIK subcutaneous injection as a starting/induction dose on July 14, 2026 (after a priority-review extension pushed the original PDUFA date to August 24), with a U.S. launch planned for late August 2026 — this should be a major topic on the call given its potential to improve the care pathway and competitive positioning versus Kisunla. - SKYCLARYS: Q1 revenue was $151 million, up 22% y/y, though the U.S. saw some inventory-driven lumpiness; ex-U.S. revenue now exceeds the U.S. for the first time as the drug is now available in 35 countries and management expects growth to keep coming from outside the U.S. - SPINRAZA: High-dose SPINRAZA is off to a strong launch (management cited roughly 20% of the U.S. patient base already submitting start forms within a month, plus similar early traction in Europe), which could help stabilize/reaccelerate a franchise that had been viewed as ex-growth. - MS legacy franchise: Continued headwinds expected from Tecfidera generic competition (especially in Europe) and Tysabri biosimilar erosion — a persistent drag on the top line that growth products need to keep offsetting.
The most significant negative pipeline news since Q1 came on July 14, 2026, when Biogen presented Phase 2 CELIA data on the tau-targeting ASO diranersen (BIIB080) at the Alzheimer's Association International Conference. The stock fell roughly 6% as the data disappointed: while diranersen achieved unprecedented tau tangle reduction and low-dose patients showed a 26% slower cognitive decline versus placebo, the effect was inversely related to dose and the trial missed its pre-specified dose-response endpoint. Analyst reaction was split — William Blair questioned the probability of Phase III success given the lack of dose-dependency, while RBC called the sell-off a buying opportunity, noting management still plans to advance to a larger Phase 3 study, with results years away. Expect analysts to press management for clarity on the go/no-go framework and next steps for this program on the call.
Biogen exited Q1 with $4.7 billion of cash and marketable securities and $1.5 billion of net debt, generating $594 million of free cash flow in the quarter. With Apellis funded via $3.6 billion of cash plus $2 billion of new bank borrowings, watch for updates on deleveraging pace and whether management signals further business-development appetite — on the Q1 call, Viehbacher indicated the company would be "more opportunistic" on larger M&A going forward, focusing incremental BD on early-stage/pre-IND assets rather than another large deal.
This is a transition-quarter print: reported EPS will look weak year-over-year largely due to disclosed, one-time acquisition and milestone-related charges (~$0.95/share in Q2 alone), not eroding fundamentals. The real story investors should focus on is (1) underlying growth-product momentum (Leqembi, Skyclarys, high-dose Spinraza) continuing to outpace legacy MS erosion, (2) the market's first real look at combined Biogen-Apellis financials and updated multi-year guidance, and (3) pipeline read-through following the mixed diranersen data, with litifilimab's SLE Phase 3 readouts now the next major near-term catalyst.